Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
2.56B | 2.63B | 2.66B | 2.66B | 1.88B |
Gross Profit | ||||
1.69B | 1.72B | 1.71B | 1.71B | 1.25B |
EBIT | ||||
-275.60M | -734.70M | -3.93B | 590.20M | 42.48M |
EBITDA | ||||
456.60M | -10.50M | -3.01B | 532.15M | 52.38M |
Net Income Common Stockholders | ||||
-668.00M | -911.20M | -3.96B | -3.96B | -270.45M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
295.20M | 370.70M | 348.80M | 348.80M | 430.88M |
Total Assets | ||||
11.49B | 12.71B | 13.94B | 13.94B | 20.18B |
Total Debt | ||||
4.59B | 4.81B | 5.10B | 5.10B | 5.61B |
Net Debt | ||||
4.30B | 4.44B | 4.76B | 4.76B | 5.18B |
Total Liabilities | ||||
6.35B | 6.71B | 7.13B | 7.13B | 8.26B |
Stockholders Equity | ||||
5.14B | 5.99B | 6.81B | 6.81B | 11.93B |
Cash Flow | Free Cash Flow | |||
357.50M | 501.70M | 306.40M | 306.40M | 205.22M |
Operating Cash Flow | ||||
646.60M | 744.20M | 509.30M | 509.30M | 323.77M |
Investing Cash Flow | ||||
-236.70M | -237.40M | 57.30M | 57.30M | -4.04B |
Financing Cash Flow | ||||
-470.10M | -496.50M | -759.20M | -759.20M | 4.03B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $3.48B | 80.45 | 9.65% | ― | 41.86% | 96.57% | |
72 Outperform | $2.95B | 21.34 | 16.64% | ― | 1.07% | -13.39% | |
62 Neutral | $2.65B | 15.67 | 9.55% | ― | -7.88% | -14.39% | |
59 Neutral | $9.97B | 10.09 | -6.45% | 3.08% | 7.41% | -11.59% | |
53 Neutral | $2.64B | ― | -32.07% | ― | 23.79% | 4.10% | |
47 Neutral | $2.27B | ― | -11.44% | ― | -2.74% | 34.70% | |
46 Neutral | $2.63B | 267.98 | -2.46% | ― | -5.65% | 78.20% |
On February 19, 2025, Clarivate reported its fourth quarter and full year 2024 financial results, showing a total revenue decrease to $2.56 billion from $2.63 billion in 2023. Despite a decreased net loss for the year, the company is actively shifting from transactional to subscription-based revenue, investing in AI-powered products, and considering strategic alternatives such as divestitures. Clarivate also repurchased $200 million in shares and prepaid $198 million of debt in 2024, with a new share repurchase program authorized for 2025-2026.